Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium, Inc. develops novel therapeutics for severe autoimmune and inflammatory disorders. News about EQ centers on EQ504, the company’s investigational aryl hydrocarbon receptor, or AhR, modulator, including preclinical data, clinical-development planning, and disease-area positioning in ulcerative colitis, other gastrointestinal diseases, and inflammatory lung diseases.
Company updates also cover financing activity, operating results, corporate presentations, and equity-award disclosures under Nasdaq inducement-grant rules. These items reflect Equillium’s focus on immunobiology, immunomodulatory assets, capital resources for research and development, and public-company compensation and governance practices.
Equillium announced plans to initiate a pivotal study of itolizumab for acute graft-versus-host disease (GVHD) after positive topline data from the EQUATE study. Interim safety data from asthma patients in the Phase 1b EQUIP study was also reported. Financially, R&D expenses increased to $7.0 million, with a net loss of $10.3 million for Q3 2021. Equillium maintains a cash balance of $90.7 million, projected to fund operations into 2023. Guidance for topline EQUIP data is set for Q4, with pivotal study commencement expected early 2022.
Equillium (Nasdaq: EQ) is set to participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 12:20 PM PT and the Jefferies Virtual London Healthcare Conference on November 18, 2021, at 12:00 AM PT. The presentations will cover the mechanism of action of itolizumab, aimed at treating severe autoimmune disorders. Leadership will conduct one-on-one meetings at both conferences. Webcast access is available on the company’s website, along with archive replays for 90 days.
Equillium (NASDAQ: EQ) released positive interim data from the Phase 1b EQUALISE study of its drug itolizumab for patients with systemic lupus erythematosus (SLE). Results showed up to a 53% decrease in proteinuria, indicating potential kidney protection. The treatment was well tolerated, with mild to moderate side effects reported. Pharmacodynamic data revealed dose-dependent reductions in the inflammatory marker CD6. These findings support the drug's mechanism targeting the CD6-ALCAM pathway and highlight the ongoing research into its efficacy for SLE and lupus nephritis.
Equillium, Inc. (NASDAQ: EQ) announced interim results from its Phase 1b EQUIP study evaluating itolizumab in patients with moderate to severe uncontrolled asthma. The study demonstrated that itolizumab was well tolerated, with a reduction in asthma control questionnaire scores from 2.5 to 1.5 at Day 29. The mean FEV-1 improved from 2.1 to 2.4 by Day 29, maintaining this improvement at Day 85. Adverse events were mainly mild to moderate. Topline data is expected later this year, highlighting itolizumab's potential in treating severe asthma.
Equillium, Inc. (Nasdaq: EQ) has announced the acceptance of two abstracts for presentation at the American Society of Hematology's 63rd annual meeting, taking place from December 11-14, 2021. The presentations will focus on Itolizumab, a novel targeted therapy for acute graft-versus-host disease (GVHD). Dr. John Koreth from Dana Farber will present one abstract on the drug's efficacy in treating newly diagnosed acute GVHD, while another, led by Equillium's Dalena Chu, discusses CD6 antigenic modulation. Both abstracts will also be published in Blood's November supplemental issue.
Equillium announced promising interim data from the EQUALISE study on itolizumab for systemic lupus erythematosus (SLE). Notably, patients showed a reduction of 42% in proteinuria and 54% in albuminuria after treatment. The study involved 35 SLE patients and confirmed that itolizumab was well tolerated at doses from 0.4 to 2.4 mg/kg. Findings suggest it could be effective in treating SLE and related complications, with further data expected from ongoing research.
Equillium, Inc. (Nasdaq: EQ) has announced the acceptance of two abstracts for presentation at the virtual 2021 American Society of Nephrology Annual Meeting, taking place from November 4-7, 2021. The abstracts focus on itolizumab, a novel anti-CD6 antibody, and highlight its safety and efficacy in treating systemic lupus erythematosus (SLE). The EQUALISE study evaluates itolizumab's effects on patients with SLE and lupus nephritis. Itolizumab is designed to modulate immune responses in severe autoimmune disorders.
Equillium, Inc. (Nasdaq: EQ) has announced that three abstracts will be presented at the ACR Convergence from November 3-10, highlighting the use of itolizumab for treating systemic lupus erythematosus (SLE) and lupus nephritis. The abstracts report on safety results from the Phase 1b EQUALISE study, pharmacodynamic markers, and the potential role of urinary ALCAM as a biomarker for renal disease activity. Itolizumab is a first-in-class monoclonal antibody targeting the CD6-ALCAM pathway, aimed at managing severe autoimmune disorders.
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology firm, will participate in the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27 to 30, 2021. On September 29 at 10:40 AM ET, CEO Bruce Steel and CMO Dolca Thomas will discuss itolizumab's mechanism and ongoing clinical programs, particularly its Phase 1b EQUATE study in acute graft-versus-host disease (aGVHD).
A live webcast will be available at Equillium's website, with an archived replay for 90 days.
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The virtual presentation, available starting September 13 at 7:00 am ET, will cover itolizumab's mechanism of action and ongoing clinical programs. Key highlights include topline data from the Phase 1b EQUATE study in acute graft-versus-host disease (aGVHD) and upcoming pivotal Phase 3 study. The webcast will be accessible for 90 days on their website.